|
Sunifiram (DM-235) is a piperazine derived research chemical which has nootropic effects in animal studies with significantly higher potency than piracetam. A number of related compounds are known, including unifiram (DM-232). ==Mechanisms== # Sunifiram activates AMPA-mediated neurotransmission. # It enhances LTP in a bell-shaped dose–response relationship. This enhancement by sunifiram is associated with an increase in phosphorylation of AMPAR through activation of protein kinase II (CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). More specifically, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCα activation through Src kinase. Enhancement of PKCα activity triggers hippocampal LTP through CaMKII activation. # Sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation. PKC activation may be a common mechanism amongst cognition stimulating drugs from different chemical classes. # Sunifiram aids in the release of acetylcholine in the cerebral cortex. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Sunifiram」の詳細全文を読む スポンサード リンク
|